Entering text into the input field will update the search result below

NeuroVive Best Performance On Swedish Stock Exchange Since Year End

Jun. 25, 2014 7:58 AM ET
Maas Biolab profile picture
Maas Biolab's Blog
12 Followers
Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

https://www.avanza.se/placera/redaktionellt/2014/06/25/neurovive-arets-kursvinnare.html

NeuroVive year's winner

Kl. 12:38, June 25, 2014

Stock market research company NeuroVive is the company that did best on the Stockholm Stock Exchange (OMX NASDAQ Stockholm) since year-end.

On the Small Cap list is NeuroVive that tops the winning group with an increase of 171 percent.

The company develops products for the treatment of acute heart and nerve cell damage by mitochondrial protection. During early summer, NeuroVive signed new agreements while insiders have been frequent buyers of shares.

Tomas Linnala tomas.linnala @ placera.nu

(Translated from Swedish)

Disclosure: The author is long NEVPF.

Additional disclosure: Maas Biolab is the largest single owner of NeuroVive Pharmaceutical stock holding about 13%.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You